Efficacy News and Research

RSS

Cedars-Sinai physicians to lead St. Jude Medical's transcatheter aortic valve implantation clinical trial

St. Jude Medical, Inc., a global medical device company, today announced that physicians from the Cedars-Sinai Heart Institute will lead the company's transcatheter aortic valve implantation (TAVI) clinical trial. The study will evaluate the safety and efficacy of the St. Jude Medical transcatheter aortic valve for patients who experience severe aortic stenosis and who may be at an elevated risk for open-heart surgery.

29 Sep 2010

Malaria vaccine development meeting begins in Washington

Agence France-Presse reports on a malaria vaccine development meeting that kicks off Tuesday in Washington, D.C.One of the stars at the meeting will be the RTS,S malaria vaccine, which has been developed by GlaxoSmithKline and the PATH Malaria Vaccine Initiative, with funding from the Bill & Melinda Gates Foundation, the news service writes.

29 Sep 2010

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Synosia Therapeutics today announced the first clinical study results showing that SYN-118 provides clinically meaningful benefits to Parkinson's patients, has a good safety profile and is well tolerated. Results from an open-label, proof-of-mechanism study of SYN-118 (CL02) were presented at the World Parkinson Congress in Glasgow, Scotland.

29 Sep 2010

Intrauterine devices for treatment of endometrial cancer

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want.

29 Sep 2010

CRP levels vary between ethnically-diverse populations: Study

C-reactive protein (CRP) levels vary between ethnically-diverse populations, and are only partly due to known differences in heart risk among these groups.A single risk level of CRP at 2 mg/L may over or under estimate the need for statin medication in different ethnic groups, especially if other risk factors are not considered.

29 Sep 2010

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%-72% as compared with placebo.

29 Sep 2010

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.

29 Sep 2010

Further trials needed to determine clinical application of Abatacept in SLE

Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together. Full details of the phase IIb clinical trial are published in the October issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

29 Sep 2010

New disposable, microfluidic PDMS device for identification of advanced breast cancer

A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.

29 Sep 2010

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

HUYA Bioscience International, the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA.

29 Sep 2010

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 2 clinical trial in Canada with its novel defensin-mimetic antibiotic, PMX-30063.

28 Sep 2010

Neuronix to present TMS treatment trial data for Alzheimer's disease at Geneva Congress

The results of a successful clinical trial using Neuronix Ltd., a developer of a patent-pending, non-invasive system for Alzheimer's Disease and related conditions, will be presented for the first time today at the annual Congress of the European Federation of Neurological Societies in Geneva, Switzerland.

28 Sep 2010

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Galapagos NV announced today that it has started a Phase II clinical study for the Company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis. In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011.

28 Sep 2010

SORT-OUT IV trial compares XIENCE V, CYPHER Stent in major acute coronary events

Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.

28 Sep 2010

Study investigates link between cough and reflux events using sound recording device

Coughing episodes are closely related to gastroesophageal reflux symptoms in patients who experience chronic cough, irrespective of other diagnoses, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

28 Sep 2010

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control.

28 Sep 2010

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee found that the combination of sunitinib with prednisone was unlikely to improve overall survival when compared to prednisone alone.

28 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.

27 Sep 2010

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC).

27 Sep 2010

Efficacy News and Research

Cedars-Sinai physicians to lead St. Jude Medical's transcatheter aortic valve implantation clinical trial

Malaria vaccine development meeting begins in Washington

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Intrauterine devices for treatment of endometrial cancer

CRP levels vary between ethnically-diverse populations: Study

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

Further trials needed to determine clinical application of Abatacept in SLE

New disposable, microfluidic PDMS device for identification of advanced breast cancer

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

Neuronix to present TMS treatment trial data for Alzheimer's disease at Geneva Congress

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

SORT-OUT IV trial compares XIENCE V, CYPHER Stent in major acute coronary events

Study investigates link between cough and reflux events using sound recording device

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News